Metsera Stock Jumps 60% on $7.3 Billion Bid by Pfizer for Anti-Obesity Drug

1. Pfizer acquires Metsera for $7.3 billion, entering anti-obesity market. 2. Deal includes performance milestones increasing total payment per share. 3. Pfizer had previously halted its weight-loss drug development earlier this year. 4. Post-announcement, Metsera shares soared 59%; Pfizer shares rose 1.5%. 5. Eli Lilly and Novo Nordisk dominate the current anti-obesity market.